Objectives This study assessed the ability of the SYNTAX score (SXscore) to stratify risk in patients treated with percutaneous coronary intervention (PCI) using zotarolimus-eluting or everolimus-eluting stents. Background The SXscore can identify patients treated with PCI who are at highest risk of adverse events. Methods The SXscore was calculated prospectively in 2,033 of the 2,292 patients enrolled in the RESOLUTE All Corners study (RESOLUTE III All Corners Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). Clinical outcomes in terms of a patient-oriented composite endpoint (POCE) of all-cause death, myocardial infarction (MI), and repeat revascularization; the individual components of POCE; target lesion failure (TLF) (a composite of cardiac death, target-vessel MI, and clinically driven target lesion revascularization); and stent thrombosis were subsequently stratified according to SXscore tertiles: SXscore(LOW) <= 9 (n = 698), 9 < SXscore(MID) <= 17 (n = 676); SXscore(HIGH) > 17 (n = 659). Results At 12-month follow-up, rates of POCE, MI, repeat revascularization, TLF, and the composite of death/MI were all significantly higher in patients in the highest SXscore tercile. Rates of stent thrombosis were all highest in the SXscore(HIGH) tertile (p > 0.05). After multivariate adjustment, the SXscore was identified as an independent predictor of POCE, MI, repeat revascularization, and TLF (p < 0.05 for all). At 12-month follow-up, the SXscore, ACEF score, and Clinical SXscore had C-statistics of 0.57, 0.78, and 0.67, respectively, for mortality and of 0.62, 0.56, 0.63, respectively, for POCE. No significant between-stent differences were observed for TLF or POCE in any of the SXscore tertiles. Conclusions The SYNTAX score is able to stratify risk amongst an all-corners population treated with PCI with second-generation drug-eluting stents (DES); however, improvements can be made with the inclusion of clinical variables. (RESOLUTE III All Comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention; NCT00617084) (J Am Coll Cardiol Intv 2011;4:432-41) (C) 2011 by the American College of Cardiology Foundation
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents : a substudy of the RESOLUTE All Comers Trial / S. Garg, P.W. Serruys, S. Silber, J. Wykrzykowska, R.J. van Geuns, G. Richardt, P. E. Buszman, H. Kelbæk, A. J. van Boven, S. H. Hofma, A. Linke, V. Klauss, W. Wijns, C. Macaya, P. Garot, C. DiMario, G. Manoharan, R. Kornowski, T. Ischinger, A.L.G. Bartorelli, E. Van Remortel, J. Ronden, S. Windecker. - In: JACC: CARDIOVASCULAR INTERVENTIONS. - ISSN 1936-8798. - 4:4(2011 Apr), pp. 432-441.
|Titolo:||The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents : a substudy of the RESOLUTE All Comers Trial|
|Parole Chiave:||Sirolimus ; Humans ; Linear Models ; Aged ; Europe ; Israel ; Angioplasty, Balloon, Coronary ; Risk Assessment ; Health Status Indicators ; Treatment Outcome ; Myocardial Infarction ; Time Factors ; Male ; Predictive Value of Tests ; Cardiovascular Agents ; Coronary Restenosis ; Kaplan-Meier Estimate ; Prospective Studies ; Survival Rate ; Risk Factors ; Prosthesis Design ; Middle Aged ; Drug-Eluting Stents ; Female ; Coronary Artery Disease ; Proportional Hazards Models|
|Settore Scientifico Disciplinare:||Settore MED/11 - Malattie dell'Apparato Cardiovascolare|
|Data di pubblicazione:||apr-2011|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.jcin.2011.01.008|
|Appare nelle tipologie:||01 - Articolo su periodico|